Singlera Genomics Raises $20 Million in Series A Round Led by Lilly Asia

Singlera Genomics, a San Diego-Shanghai genetic testing company, raised $20 million in a Series A funding from China investors, led by Lilly Asia Ventures. Singlera describes itself as focused on personalized medicine, with interests in cancer diagnosis and non-invasive prenatal diagnosis. Founded in 2014, Singlera has an R&D center in San Diego and a business-clinical operation in Shanghai. The funding was joined by Green Pine Capital Partners, CDBI Partners and others. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.